Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

BPC-157

CPreclinical

Gastric pentadecapeptide · 15 amino acids

Not FDA ApprovedWADA Banned

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Preclinical research suggests it may accelerate wound healing and protect organs from damage.

Mechanism of Action

Modulates nitric oxide synthesis and upregulates growth factor expression including VEGF and EGF. Interacts with the dopaminergic and GABAergic systems.

Benefits

  • Accelerated tendon and ligament healing in animal models
  • Gastric ulcer protection demonstrated in rats
  • Potential neuroprotective properties
  • Reduced inflammation in preclinical studies
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

BPC-157 — Dosing in Published Research

Reported Routes: Subcutaneous injection, Oral
Research protocols typically use 200-800 mcg/day in animal studies. No established human dosing due to lack of clinical trials.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Limited human safety data available
  • Nausea reported anecdotally
  • Injection site reactions
  • Unknown long-term effects

Considering Peptide Research?

BPC-157 is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider
Always Consult a Professional

Research & Evidence

ReviewJournal of Physiology and Pharmacology, 2022

BPC 157: Overview of regenerative properties

Comprehensive review of BPC-157 regenerative mechanisms across multiple organ systems in animal models

PMID: 35142708
ReviewCurrent Pharmaceutical Design, 2018

BPC 157 and its role in accelerating wound healing

Demonstrated acceleration of wound healing through angiogenic and anti-inflammatory pathways in rats

PMID: 29863423
AnimalBiomedicines, 2020

Stable gastric pentadecapeptide BPC 157 and tendon healing

BPC-157 improved Achilles tendon healing outcomes in rat transection models

PMID: 32225170

Compare BPC-157 With

References

  1. 1. BPC 157: Overview of regenerative properties. Journal of Physiology and Pharmacology, 2022. Comprehensive review of BPC-157 regenerative mechanisms across multiple organ systems in animal models [PMID: 35142708]
  2. 2. BPC 157 and its role in accelerating wound healing. Current Pharmaceutical Design, 2018. Demonstrated acceleration of wound healing through angiogenic and anti-inflammatory pathways in rats [PMID: 29863423]
  3. 3. Stable gastric pentadecapeptide BPC 157 and tendon healing. Biomedicines, 2020. BPC-157 improved Achilles tendon healing outcomes in rat transection models [PMID: 32225170]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

BPC-157 FAQ

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.